T. Jacobs

1.6k total citations
23 papers, 1.2k citations indexed

About

T. Jacobs is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, T. Jacobs has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 5 papers in Pharmacology and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in T. Jacobs's work include Bipolar Disorder and Treatment (19 papers), Electroconvulsive Therapy Studies (9 papers) and Schizophrenia research and treatment (8 papers). T. Jacobs is often cited by papers focused on Bipolar Disorder and Treatment (19 papers), Electroconvulsive Therapy Studies (9 papers) and Schizophrenia research and treatment (8 papers). T. Jacobs collaborates with scholars based in United States, Singapore and United Kingdom. T. Jacobs's co-authors include Mauricio Tohen, Gary D. Tollefson, Peter D. Feldman, V. Toma, T.M. Sanger, Richard C. Shelton, S.R. David, William Buras, Kimberley S. Gannon and Wei Zhang and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Journal of Affective Disorders.

In The Last Decade

T. Jacobs

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Jacobs United States 9 1.0k 374 155 146 100 23 1.2k
Michael Banov United States 12 862 0.9× 253 0.7× 92 0.6× 114 0.8× 91 0.9× 15 1.1k
WFSBP Task Force on Treatment Guide United States 8 1.1k 1.1× 408 1.1× 274 1.8× 110 0.8× 144 1.4× 8 1.4k
Steven K. Secunda United States 21 831 0.8× 289 0.8× 221 1.4× 137 0.9× 142 1.4× 33 1.2k
Adam Ruth United States 13 791 0.8× 275 0.7× 121 0.8× 41 0.3× 110 1.1× 28 961
S. Corya United States 13 783 0.8× 653 1.7× 197 1.3× 33 0.2× 202 2.0× 26 1.1k
P.V. Tran United States 7 938 0.9× 258 0.7× 174 1.1× 62 0.4× 54 0.5× 15 1.2k
Dennis Sweitzer United States 11 672 0.7× 196 0.5× 142 0.9× 44 0.3× 49 0.5× 13 833
Margaretta Nyilas United States 15 1.2k 1.1× 427 1.1× 313 2.0× 184 1.3× 78 0.8× 28 1.4k
J. K. Larsen Denmark 13 494 0.5× 187 0.5× 101 0.7× 92 0.6× 48 0.5× 17 703
P. J. Perry United States 12 526 0.5× 216 0.6× 93 0.6× 66 0.5× 89 0.9× 20 872

Countries citing papers authored by T. Jacobs

Since Specialization
Citations

This map shows the geographic impact of T. Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Jacobs more than expected).

Fields of papers citing papers by T. Jacobs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Jacobs. The network helps show where T. Jacobs may publish in the future.

Co-authorship network of co-authors of T. Jacobs

This figure shows the co-authorship network connecting the top 25 collaborators of T. Jacobs. A scholar is included among the top collaborators of T. Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Jacobs. T. Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Evans, Angela R., M. Tohen, Andreas Marneros, et al.. (2003). P.1.092 Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial. European Neuropsychopharmacology. 13. S213–S213. 21 indexed citations
2.
Sanger, T.M., Mauricio Tohen, Eduard Vieta, et al.. (2002). Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. Journal of Affective Disorders. 73(1-2). 155–161. 50 indexed citations
3.
Frazier, Jean A., Joseph Biederman, Mauricio Tohen, et al.. (2001). A Prospective Open-Label Treatment Trial of Olanzapine Monotherapy in Children and Adolescents with Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology. 11(3). 239–250. 155 indexed citations
4.
Shelton, Richard C., Gary D. Tollefson, Mauricio Tohen, et al.. (2001). A Novel Augmentation Strategy for Treating Resistant Major Depression. American Journal of Psychiatry. 158(1). 131–134. 378 indexed citations
5.
Chengappa, KN Roy, Mauricio Tohen, Joseph Levine, et al.. (2000). Response to placebo among bipolar I disorder patients experiencing their first manic episode. Bipolar Disorders. 2(4). 332–335. 6 indexed citations
6.
Jacobs, T., et al.. (2000). Safety of the novel antipsychotic olanzapine in the treatment of bipolar I disorder. Schizophrenia Research. 41(1). 193–193. 4 indexed citations
7.
Jacobs, T., K.S. Gannon, T.M. Sanger, et al.. (2000). Olanzapine: Acute and long-term efficacy in bipolar I patients. Schizophrenia Research. 41(1). 192–193. 6 indexed citations
8.
Tohen, Mauricio, T. Jacobs, P.D. Feldman, et al.. (2000). 275. Is olanzapine a mood-stabilizer?. Biological Psychiatry. 47(8). S83–S83. 3 indexed citations
9.
Frazier, Jean A., Mauricio Tohen, Joseph Biederman, et al.. (2000). Olanzapine in the treatment of juvenile bipolar disorder. European Neuropsychopharmacology. 10. 247–247. 3 indexed citations
10.
Frazier, Jean A., Joseph Biederman, T. Jacobs, et al.. (2000). Olanzapine in the treatment of bipolar-disorder in juveniles. Schizophrenia Research. 41(1). 194–194. 11 indexed citations
11.
Shelton, Richard C., et al.. (2000). The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. Schizophrenia Research. 41(1). 193–193. 6 indexed citations
12.
Tohen, Mauricio, T.M. Sanger, Susan L. McElroy, et al.. (1999). Olanzapine Versus Placebo in the Treatment of Acute Mania. American Journal of Psychiatry. 156(5). 702–709. 443 indexed citations
13.
Shelton, Richard C., et al.. (1999). Olanzapine plus fluoxetine: Double-blind and open-label results in treatment-resistant major depressive disorder. European Neuropsychopharmacology. 9. 246–246. 8 indexed citations
14.
Jacobs, T., K.S. Gannon, T.M. Sanger, et al.. (1999). Long-term olanzapine treatment: Efficacy and safety in manic patients with and without psychotic features. European Neuropsychopharmacology. 9. 247–247. 3 indexed citations
15.
Namjoshi, M., T. Jacobs, T.M. Sanger, et al.. (1999). Changes in health-related quality of life of patients with bipolar disorder treated with olanzapine. European Neuropsychopharmacology. 9. 245–246. 3 indexed citations
16.
Tohen, M., et al.. (1999). Olanzapine in the treatment of mania: A placebo-controlled four-week study. European Neuropsychopharmacology. 9. 247–247. 4 indexed citations
17.
Sanger, T.M., T. Jacobs, K.S. Gannon, et al.. (1999). Olanzapine in the treatment of rapid-cycling Bipolar I patients. European Neuropsychopharmacology. 9. 246–246. 5 indexed citations
18.
Tohen, Mauricio, T.M. Sanger, Gary D. Tollefson, et al.. (1998). Olanzapine versus placebo in the treatment of acute mania. European Neuropsychopharmacology. 8. S178–S178. 7 indexed citations
19.
Tollefson, G.D., Richard C. Shelton, S. Stahl, et al.. (1998). Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features. European Neuropsychopharmacology. 8. S178–S178. 3 indexed citations
20.
Sanger, T.M., et al.. (1998). Olanzapine vs. placebo in rapid-cycling bipolar disorder. Schizophrenia Research. 29(1-2). 152–152. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Banov Breakdown of academic impact, for papers by WFSBP Task Force on Treatment Guide Breakdown of academic impact, for papers by Steven K. Secunda Breakdown of academic impact, for papers by Adam Ruth Breakdown of academic impact, for papers by S. Corya Breakdown of academic impact, for papers by P.V. Tran Breakdown of academic impact, for papers by Dennis Sweitzer Breakdown of academic impact, for papers by Margaretta Nyilas Breakdown of academic impact, for papers by J. K. Larsen Breakdown of academic impact, for papers by P. J. Perry
Rankless by CCL
2026